Is the 18F-FDG PET/CT the definite resource to detect the recurrence on high-risk thyroid cancer patients?

Affiliations

Editorial

Carlos Alberto Buchpiguel. Arch Endocrinol Metab. 2017 Oct.

. 2017 Oct;61(5):411-413.

doi: 10.1590/2359-3997000000300.

¹ Departamento de Radiologia e Oncologia da Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brasil.

No abstract available

Conflict of interest statement

Disclosure: no potential conflict of interest relevant to this article was reported.

1. Kitahara CM, Devesa SS, Sosa JA. Increases in Thyroid Cancer Incidence and Mortality-Reply. JAMA. 2017;318(4):390-1. - PubMed
1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. - PMC - PubMed
1. Machado MR, Tavares MR, Buchpiguel CA, Chammas MC. Ultrasonographic Evaluation of Cervical Lymph Nodes in Thyroid Cancer. Otolaryngol Head Neck Surg. 2017;156(2):263-71. - PubMed
1. Kendi ATK, Mudalegundi S, Switchenko J, Lee D, Halkar R, Chen AY. Assessment of the Role of Different Imaging Modalities with Emphasis on Fdg Pet/Ct in the Management of Well Differentiated Thyroid Cancer (WDTC). J Thyroid Disord Ther. 2016;5.pii:202. - PMC - PubMed
1. Okada J, Oonishi H, Yoshikawa K, Imaseki K, Uno K, Itami J, et al. FDG-PET for the evaluation of tumor viability after anticancer therapy. Ann Nucl Med. 1994;8(2):109-13. - PubMed